Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IKT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIKT switches auditors from CohnReznick to Deloitte; prior material weakness remediated
Filed August 26, 2026 · Period ending August 21, 2026 · ~1 min read
Key Changes
-
medium
Dismissed CohnReznick and appointed Deloitte & Touche as independent auditor for fiscal 2026, effective August 21. CohnReznick issued clean audit opinions for 2025 and 2024 with no disagreements on accounting principles.
Item 4.01 — Changes in Registrant's Certifying Accountant verify on EDGAR → -
medium
A material weakness in internal controls over financial reporting was identified during fiscal 2024 but was remediated by September 30, 2024, before the auditor change.
Item 4.01 — Changes in Registrant's Certifying Accountant verify on EDGAR →
Summary
Inhibikase Therapeutics changed auditors on August 21, 2026, dismissing CohnReznick and appointing Deloitte & Touche for fiscal year 2026. The change was a company decision rather than an auditor resignation. CohnReznick had issued unqualified audit opinions for both 2025 and 2024, and there were no disagreements on accounting principles or practices during the engagement.
The filing discloses that a material weakness in internal controls over financial reporting was identified during fiscal 2024, but this weakness was remediated by September 30, 2024—well before the auditor change. The remediation and the clean audit opinions suggest the auditor switch is a routine business decision rather than a response to audit quality or control concerns. For retail holders, this is a standard governance matter with no immediate operational or financial implications.
Section-by-Section Diff
Event · Item 4.01 — Changes in Registrant's Certifying Accountant
IKT dismissed CohnReznick and appointed Deloitte as auditor; prior material weakness was remediated before dismissal.
Added in current filing · verify on EDGAR →
On August 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”) approved the dismissal of CohnReznick LLP (“CohnReznick”) as the Company’s independent registered public accounting firm, effective immediately.
The company dismissed CohnReznick as its auditor and appointed Deloitte & Touche LLP for fiscal year 2026. The dismissal was a company decision, not an auditor resignation. CohnReznick's audit reports for 2025 and 2024 were unqualified, and there were no disagreements on accounting principles or practices.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The audit reports of CohnReznick on the Company’s consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
CohnReznick issued clean, unqualified audit opinions for both 2025 and 2024, with no modifications or qualifications. This indicates the auditor change was routine and not driven by audit quality concerns.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 27, 2026 · How we verify